Banner - NPPA Connect
Logo Image
Opinion|Videos|June 6, 2024

Real-World Clinical Experience With Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis

In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management.

Episodes in this series
  1. In your experience, what are the most commonly cited reasons by healthcare providers for switching treatments in patients with AD? 
  2. In your experience, how might these factors vary across different stages of the disease or patient populations?
  3. How do you interpret the implications of the majority of patients experiencing improved disease control upon transitioning to ruxolitinib cream, particularly concerning disease management strategies and patient outcomes?

Related Content

Latest CME

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches
Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

View more
Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care
Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

View more